The future of antibodies in toxicology is promising, with ongoing research focused on enhancing their specificity and stability. Emerging technologies, such as nanobodies and recombinant antibodies, are being explored for their potential to offer more robust and cost-effective solutions. Additionally, the integration of bioinformatics and machine learning is anticipated to accelerate the development of antibody-based diagnostics and therapeutics.
